Gary Schiller, MD, UCLA Medical Center
Advertisement
Articles by Gary Schiller, MD, UCLA Medical Center
Advertisement
Latest Updated Articles
Standard of Care for BPDCN TreatmentPublished: August 20th 2020 | Updated:
Novel Agents for BPDCN ManagementPublished: August 20th 2020 | Updated:
Treatment Approach Amid COVID-19 PandemicPublished: August 20th 2020 | Updated:
Second-Line Treatment OptionsPublished: August 20th 2020 | Updated:
BPDCN Prevalence, Patient Profile, and Work-UpPublished: August 20th 2020 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
Long-Term Cilta-Cel Data Show Low Rates of PFS Events in Standard-Risk R/R Myeloma
2
FDA Updates Axi-Cel Label to Remove Limitation of Use in R/R PCNSL
3
Nonresponse to Bridging Therapy and Peak ALC After Cilta-Cel Are Associated With Neurotoxicity, NRM in Myeloma
4
Real-World Data Support Clinical Benefit With Lifileucel in Previously Treated Advanced Melanoma
5